^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    ProMark™

    Company:
    Metamark Genetics
    Type:
    Laboratory Developed Test

    Details

    Evidence
    News
    ProMark is a first-of-its-kind protein-based prognostic test for prostate cancer. It utilizes an automated image analysis technology that identifies tumor and benign tissue, ProMark measures the quantitative expression levels of eight protein biomarkers that individually correlate with tumor aggressiveness in patients with biopsy Gleason Scores of 3+3 and 3+4. This unique approach allows ProMark to outperform conventional gene expression-based diagnostic assays
    Cancer:
    Prostate Cancer
    Gene:
    CUL2 (Cullin 2), DERL1 (Derlin 1), FUS (FUS RNA Binding Protein), HSPA9 (Heat Shock Protein Family A (Hsp70) Member ), Pdss2 (Prenyl (solanesyl) diphosphate synthase subunit 2), SMAD4 (SMAD family member 4)
    See More ...